Patents by Inventor Thomas Hoeg-Jensen

Thomas Hoeg-Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22
    Publication number: 20240108731
    Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.
    Type: Application
    Filed: June 30, 2023
    Publication date: April 4, 2024
    Inventors: Kristian SASS-ØRUM, Rasmus JØRGENSEN, Sebastian Beck JØRGENSEN, Henning THØGERSEN, Thomas HOEG-JENSEN, Michael Paolo Bastner SANDRINI
  • THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22
    Publication number: 20230381320
    Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.
    Type: Application
    Filed: June 30, 2023
    Publication date: November 30, 2023
    Inventors: Kristian SASS-ØRUM, Rasmus JØRGENSEN, Sebastian Beck JØRGENSEN, Henning THØGERSEN, Thomas HOEG-JENSEN, Michael Paolo Bastner SANDRINI
  • Therapeutic derivatives of interleukin-22
    Patent number: 11806403
    Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: November 7, 2023
    Assignee: CytoKi Pharma ApS
    Inventors: Kristian Sass-Ørum, Rasmus Jørgensen, Sebastian Beck Jørgensen, Henning Thøgersen, Thomas Hoeg-Jensen, Michael Paolo Bastner Sandrini
  • GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES
    Publication number: 20230331745
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
    Type: Application
    Filed: June 16, 2023
    Publication date: October 19, 2023
    Inventors: Thomas Kruse, Mikael Kofod-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald Rasmussen, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • Glucose-sensitive albumin-binding derivatives
    Patent number: 11767332
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: September 26, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse, Mikael Kofod-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald Rasmussen, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • Glucose sensitive insulins and uses thereof
    Patent number: 11541122
    Abstract: The present invention provides glucose sensitive insulin derivatives comprising a macrocycle, a glucose mimetic and human insulin or an analogue thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such glucose sensitive insulin derivatives, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: January 3, 2023
    Inventors: Thomas Hoeg-Jensen, Alice Ravn Madsen, Thomas Kruse, Per Sauerberg, Anthony Murray, Andrew Michael Chapman, Anthony Peter Davis
  • Therapeutic Derivatives of Interleukin-22
    Publication number: 20220347304
    Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.
    Type: Application
    Filed: May 5, 2022
    Publication date: November 3, 2022
    Inventors: Kristian SASS-ØRUM, Rasmus Jørgensen, Sebastian Beck Jørgensen, Henning Thøgersen, Thomas Hoeg-Jensen, Michael Paolo Bastner Sandrini
  • GLUCOSE SENSITIVE INSULIN DERIVATIVES
    Publication number: 20220184184
    Abstract: The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive albumin binding. The invention also relates to novel intermediates. Finally, the invention provides a pharmaceutical composition comprising the insulin derivatives of the invention and the use of such a composition in the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 16, 2022
    Inventors: Thomas Hoeg-Jensen, Carsten Behrens, Emiliano Clo, Martin Werner Borchsenius Muenzel, Per Sauerberg, Thomas Kruse, Jane Spetzler, Ulrich Sensfuss, Claudia Ulrich Hjoerringgaard, Henning Thoegersen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES
    Publication number: 20220081451
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
    Type: Application
    Filed: October 13, 2021
    Publication date: March 17, 2022
    Inventors: Thomas Kruse, Mikael Kofod-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald Rasmussen, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • GLUCOSE SENSITIVE INSULINS AND USES THEREOF
    Publication number: 20220047708
    Abstract: The present invention provides glucose sensitive insulin derivatives comprising a macrocycle, a glucose mimetic and human insulin or an analogue thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such glucose sensitive insulin derivatives, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: September 18, 2019
    Publication date: February 17, 2022
    Inventors: Thomas Hoeg-Jensen, Alice Ravn Madsen, Thomas Kruse, Per Sauerberg, Anthony Murray, Andrew Michael Chapman, Anthony Peter Davis
  • Insulins with polar recombinant extensions
    Patent number: 11208452
    Abstract: The present invention relates to novel insulins or insulins analogues that are extended with predominantly sequences of polar amino acid residues in order to improve the half-life and stability of the drug substance. The invention also provides pharmaceutical compositions comprising such drug substances, and relates to the use of such drug substances for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: December 28, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Tine Nygaard Vinther, Frantisek Hubalek, Ingrid Pettersson
  • Glucose-sensitive albumin-binding derivatives
    Patent number: 11186595
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X—R2, and wherein “X” is a mono- to multiatomic linker and where R1 and R2, which may be identical or different, each represents a group of Formula (11a) or (IIb) Also described are diboron conjugates represented by the general Formula (I?), which is: R1?-X?—R2?, in which either the moeities R1? or R2? or X? carry a drug that is covalently attached to the diboron compound.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: November 30, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse, Mikael Kofod-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald Rasmussen, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • Insulin compositions and method of making a composition
    Patent number: 11167035
    Abstract: The invention is related to insulin compositions with a high content of zinc atoms per six molecules of acylated insulin. The insulin is an acylated insulin and may be mixed with a further insulin analogue such as the rapid acting insulin Asp B28 human insulin.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: November 9, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Svend Havelund, Frantisek Hubalek, Helle Birk Olsen, Ib Jonassen, Thomas Hoeg-Jensen, Anne Plum, Ulla Ribel-Madsen
  • NOVEL INSULIN DERIVATIVES
    Publication number: 20210024604
    Abstract: The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.
    Type: Application
    Filed: October 7, 2020
    Publication date: January 28, 2021
    Inventors: Thomas Hoeg-Jensen, Palle Jakobsen, Ulrich Sensfuss, Christian Fledelius, Ulla Ribel-Madsen
  • GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES
    Publication number: 20200325160
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X—R2, and wherein “X” is a mono- to multiatomic linker and where R1 and R2, which may be identical or different, each represents a group of Formula (11a) or (IIb) Also described are diboron conjugates represented by the general Formula (I?), which is: R1?-X?—R2?, in which either the moeities R1? or R2? or X? carry a drug that is covalently attached to the diboron compound.
    Type: Application
    Filed: November 8, 2018
    Publication date: October 15, 2020
    Inventors: Thomas Kruse, Mikael Kofoed-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald Rasmussen, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Vanova
  • INSULIN DERIVATIVES
    Publication number: 20200172593
    Abstract: The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.
    Type: Application
    Filed: February 7, 2020
    Publication date: June 4, 2020
    Inventors: Thomas Hoeg-Jensen, Palle Jakobsen, Ulrich Sensfuss, Christian Fledelius, Ulla Ribel-Madsen
  • PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES
    Publication number: 20190112348
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 18, 2019
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • Protease stabilized acylated insulin analogues
    Patent number: 10259856
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: April 16, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • NOVEL INSULIN DERIVATIVES
    Publication number: 20180371045
    Abstract: The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.
    Type: Application
    Filed: July 20, 2018
    Publication date: December 27, 2018
    Inventors: Thomas Hoeg-Jensen, Palle Jakobsen, Ulrich Sensfuss, Christian Fledelius, Ulla Ribel-Madsen
  • INSULINS WITH POLAR RECOMBINANT EXTENSIONS
    Publication number: 20180291076
    Abstract: The present invention relates to novel insulins or insulins analogues that are extended with predominantly sequences of polar amino acid residues in order to improve the half-life and stability of the drug substance. The invention also provides pharmaceutical compositions comprising such drug substances, and relates to the use of such drug substances for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: June 2, 2016
    Publication date: October 11, 2018
    Inventors: Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Tine Nygaard Vinther, Frantisek Hubalek, Ingrid Pettersson